For example, the phase 2/3 DIAN-TU-001 trial testing gantenerumab and solanezumab in dominantly inherited AD showed that the Aβ-aggregate selective antibody gantenerumab [37], but not the Aβ monomeric selective antibody solanezumab [38] significantly decreased CSF neurogranin levels after 4 years of treatment [39]. The gene discussed is NRGN; the disease is Alzheimer disease.